aap Implantate Exploring Strategic Alternatives to Create More Value
Published: Aug 14, 2017
Press Release No. 2 dated August 14, 2017
aap Announces Exploration of Strategic Alternatives to Create More Value
aap Implantate AG (XETRA: AAQ) (“aap” or the “Company”), a globally operating medical device company headquartered in Berlin, Germany, today announced that its Management Board is exploring strategic alternatives for more value creation from, among other things, co-development-/license agreements, joint venture agreements to corporate transactions (e.g. merger, share or asset deal, carve out).
This step belongs to the Company's overall current strategic planning and related efforts to explore the full spectrum of possible options to unlock the inherent value of aap’s comprehensive trauma product portfolio and its diverse patented platform technologies as well as to build upon its strengthened financial position.
There is no set time table for this process of exploring strategic alternatives. The Company stated that no decision has been made with regard to any alternatives and that there can be no assurance that the Management Board's exploration of strategic alternatives will result in any transaction being entered into or consummated. aap does not intend to discuss or disclose developments with respect to this process until the Management Board has approved a definitive course of action or otherwise concludes the review of strategic alternatives.
This release contains forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments
For further information, please contact:
aap Implantate AG
Manager Investor Relations
Tel.: +49 (0)30 / 750 19 134
Fax: +49 (0)30 / 750 19 290